Morgan Stanley
TSHA icon

Morgan Stanley’s Taysha Gene Therapies TSHA Stock Holding History

Morgan Stanley’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.3M Sell
17,965,371
-113,147
-0.6% -$526K ﹤0.01% 1632
2025
Q4 		$99.4M Sell
18,078,518
-1,229,085
-6% -$5.97M 0.01% 1452
2025
Q3 		$63.1M Buy
19,307,603
+2,442,521
+14% +$6.92M ﹤0.01% 1815
2025
Q2 		$39M Buy
16,865,082
+18,708
+0.1% +$40.6K ﹤0.01% 2150
2025
Q1 		$23.4M Sell
16,846,374
-793,992
-5% -$1.33M ﹤0.01% 2536
2024
Q4 		$30.5M Buy
17,640,366
+9,976,373
+130% +$20.7M ﹤0.01% 2322
2024
Q3 		$15.4M Buy
7,663,993
+186,596
+2% +$409K ﹤0.01% 3057
2024
Q2 		$16.7M Buy
7,477,397
+2,308,507
+45% +$6.72M ﹤0.01% 2858
2024
Q1 		$14.8M Buy
5,168,890
+4,735,814
+1,094% +$9.87M ﹤0.01% 3000
2023
Q4 		$767K Buy
433,076
+261,007
+152% +$520K ﹤0.01% 5429
2023
Q3 		$544K Buy
172,069
+40,761
+31% +$76.1K ﹤0.01% 5131
2023
Q2 		$86.8K Buy
131,308
+43,495
+50% +$31.5K ﹤0.01% 6010
2023
Q1 		$70K Buy
87,813
+64,206
+272% +$82.9K ﹤0.01% 6145
2022
Q4 		$53.4K Sell
23,607
-1,355
-5% -$2.74K ﹤0.01% 6262
2022
Q3 		$48K Sell
24,962
-46,689
-65% -$169K ﹤0.01% 6430
2022
Q2 		$265K Sell
71,651
-104,104
-59% -$413K ﹤0.01% 5752
2022
Q1 		$1.15M Buy
175,755
+33,410
+23% +$250K ﹤0.01% 4897
2021
Q4 		$1.66M Buy
142,345
+17,251
+14% +$260K ﹤0.01% 4718
2021
Q3 		$2.33M Buy
125,094
+88,984
+246% +$1.69M ﹤0.01% 4449
2021
Q2 		$766K Buy
36,110
+13,149
+57% +$303K ﹤0.01% 5240
2021
Q1 		$466K Sell
22,961
-8,377
-27% -$227K ﹤0.01% 5191
2020
Q4 		$832K Buy
+31,338
New +$675K ﹤0.01% 4769

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Morgan Stanley's TSHA Position: Q1 2026 in Review

Morgan Stanley reduced its Taysha Gene Therapies (TSHA) stake by 0.63% in Q1 2026, selling an estimated $526K and leaving 17,965,371 shares worth $80.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Morgan Stanley first reported a position in TSHA in Q4 2020 and has held it in 22 quarters since. The position peaked at $99.4M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Morgan Stanley held 17,965,371 shares of Taysha Gene Therapies worth $80.3M as of Q1 2026.
  • Morgan Stanley sold 113,147 Taysha Gene Therapies shares in Q1 2026, an estimated $526K.
  • Taysha Gene Therapies made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #1632 holding.
  • Morgan Stanley first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 22 quarters since.
  • Morgan Stanley's Taysha Gene Therapies position peaked at $99.4M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.